Dr. Hans Lee, MD
Claim this profileM D Anderson Cancer Center
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
7 reported clinical trials
12 drugs studied
Area of expertise
1Multiple Myeloma
TP53 positive
TP53 negative
Stage IV
2Plasma Cell Neoplasms
TP53 positive
TP53 negative
Stage IV
Affiliated Hospitals
Clinical Trials Hans Lee, MD is currently running
REGN5458
for Multiple Myeloma
The main purpose of this study is to learn about the safety of REGN5458 and to find out what is the best dose of REGN5458 to give to patients with multiple myeloma. An additional purpose is to look for any signs that REGN5458 can treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving REGN5458 * How REGN5458 works in the body * How much REGN5458 is present in the blood * How REGN5458 may work to treat cancer
Recruiting1 award Phase 1 & 2
Belantamab Mafodotin
for Multiple Myeloma
This is a single-center, single arm, phase I study designed to determine the safety and find the recommended Phase 2 dose (RP2D) or maximum dose level (MTD) of Belantamab Mafodotin in patients with high-risk smoldering multiple myeloma. The study will have a dose-finding part and a dose-expansion part. The maximum number of enrolled patients will be 30 with 18 patients for the dose-finding part and 12 patients for the dose-expansion part. Once we determine the MTD or RP2D in the dose-finding part, we will enroll and treat 12 additional patients at the MTD or RP2D in the expansion part. Efficacy will be assessed through the overall response rate (ORR) at the end of the study. With the limited number of patients for the dose-expansion part, we will not have formal futility monitoring rule.
Recruiting1 award Phase 110 criteria
More about Hans Lee, MD
Clinical Trial Related1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Hans Lee, MD has experience with
- Dexamethasone
- Daratumumab
- Ixazomib
- CardioMEMS™ HF System
- Modakafusp Alfa
- Belantamab Mafodotin
Breakdown of trials Hans Lee, MD has run
Multiple Myeloma
Plasma Cell Neoplasms
Primary Amyloidosis
Heart Failure
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Hans Lee, MD specialize in?
Hans Lee, MD focuses on Multiple Myeloma and Plasma Cell Neoplasms. In particular, much of their work with Multiple Myeloma has involved TP53 positive patients, or patients who are TP53 negative.
Is Hans Lee, MD currently recruiting for clinical trials?
Yes, Hans Lee, MD is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Hans Lee, MD has studied deeply?
Yes, Hans Lee, MD has studied treatments such as Dexamethasone, Daratumumab, Ixazomib.
What is the best way to schedule an appointment with Hans Lee, MD?
Apply for one of the trials that Hans Lee, MD is conducting.
What is the office address of Hans Lee, MD?
The office of Hans Lee, MD is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.